vs
Side-by-side financial comparison of Black Rock Coffee Bar, Inc. (BRCB) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $51.5M, roughly 1.4× Black Rock Coffee Bar, Inc.). Black Rock Coffee Bar, Inc. runs the higher net margin — -1.4% vs -49.0%, a 47.6% gap on every dollar of revenue. Black Rock Coffee Bar, Inc. produced more free cash flow last quarter ($-25.8M vs $-84.7M).
Black Rock Coffee Bar, Inc. is a U.S.-based specialty coffee retail chain that offers handcrafted premium coffee beverages, energy drinks, baked goods, and light snacks. It operates in-store and drive-thru locations primarily across western U.S. states, prioritizing high-quality customizable products and community-focused consumer experiences.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
BRCB vs VRDN — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $51.5M | $70.6M |
| Net Profit | $-712.0K | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | -12.4% | -56.7% |
| Net Margin | -1.4% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $-0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.6M | $490.9M |
| Total DebtLower is stronger | $20.0M | — |
| Stockholders' EquityBook value | $43.0M | $503.0M |
| Total Assets | $323.2M | $577.1M |
| Debt / EquityLower = less leverage | 0.46× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $32.6M | $490.9M |
| Q3 25 | $20.0M | — |
| Q3 25 | $43.0M | $503.0M |
| Q3 25 | $323.2M | $577.1M |
| Q3 25 | 0.46× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $-84.6M |
| Free Cash FlowOCF − Capex | $-25.8M | $-84.7M |
| FCF MarginFCF / Revenue | -50.2% | -120.1% |
| Capex IntensityCapex / Revenue | 44.5% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-2.9M | $-84.6M |
| Q3 25 | $-25.8M | $-84.7M |
| Q3 25 | -50.2% | -120.1% |
| Q3 25 | 44.5% | 0.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
